Abstract: Hepatitis B virus （HBV） infection is popular worldwide. Chronic hepatitis B infection is the leading cause of liver cirrhosis and hepatocellular carcinoma, which is also one of the important public health problems. The occurrence of HBV-induced liver cirrhosis, disease progression, and prognosis are closely related to serum HBV DNA loads. Several studies have shown that effective inhibition of hepatitis B virus replication can improve, even reverse hepatic fibrosis, reduce the probability of long-term complications in patients with cirrhosis, improve prognosis and lower the occurrence of liver cirrhosis and hepatocellular carcinoma. Thus, effective antiviral treatments in patients with liver cirrhosis is particularly important. At present, the main antiviral agents are interferon-αand nucleos(t)ide analogues, and in recent years there are lots of progresses in terms of safety and scheme selection of them.

Key words: Liver cirrhosis, Hepatitis B, antiviral therapy